Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) changes shares on Thursday trading session, with a change of -2.99% or -$0.56 shares. The trading starts at $18.98 and closed at $18.71 throughout the day. The trading session low price was $17.265 and day high was $19.53 on Thursday, June 18. After the session, the Healthcare sector daily volume shifted to 0.13 million while its average volume is 80.86K. In other hand, the MIRM market cap reached to $436.33M.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 8.62% and up 14.01% for month. Its quarterly performance was 68.06% above, while its half year performance is up 10.07%. MIRM performance fall -25.98% for year-to-date. Current recommendation for Mirum Pharmaceuticals Inc. is 1.60.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. MIRM EPS (TTM) for 12-month is -2.89. EPS for this year is -202.90%, while for the next year its value is -4.13. Its EPS Q/Q reached -232.30%.
Let’s take a look on the analyst recommendations on MIRM for the current month and previous month. For the current month, 4 of 5 analysts recommend stock as Buy while 0 as Sell, 1 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings.
NEA Management Company, LLC, Frazier Management LLC and Deerfield Management Company, L.P. (Series C) are the top three holders in Mirum Pharmaceuticals Inc. (MIRM) stock. On Mar 30, 2020, NEA Management Company, LLC has 4.19 million shares which valued 58.63 million. On Mar 30, 2020, Frazier Management LLC owned 3.57 million shares which valued at 49.94 million. On Mar 30, 2020, Deerfield Management Company, L.P. (Series C) has a total of 3.45 million shares which valued at 48.28 million. In the end, Deerfield Management Company, L.P. (Series C) have 13.58% shares outstanding of Mirum Pharmaceuticals Inc. (MIRM) on Mar 30, 2020. The insider ownership moved to 10.32% and institutional holding shifted to 73.40%.
The company posted an EPS (TTM) of -2.89. According to the most recent quarter report on (Jun 2020), 4 analysts estimated an average EPS of -0.87, while -0.59 EPS posted a year ago period. Analyst Estimated EPS for MIRM published in the report was -0.91–0.83 during the same period. Comparing with last year, the average estimated EPS was -0.59 which is higher than -0.86 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for MIRM rise 31.01% for period of 200 days. SMA for 50 days was 10.26% which is showing green signal, while SMA-20 was 4.36%. The moving average value for Mirum Pharmaceuticals Inc. (MIRM) is 16.28 and 17.20 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in MIRM stock. On Mar 20, Tucker Edwin Jonathan, Chief Medical Officer, bought 2,500 trading shares at the cost of $11.90, which valued at 29740.0. On Mar 19, Tucker Edwin Jonathan, Chief Medical Officer, bought 2,000 shares at the cost of $9.91, with total shares of 3,500.